Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase NA 1

Status

Unknown 4Recruiting 1Not yet recruiting 1Completed 1

Sponsor Class

OTHER 111INDUSTRY 16OTHER_GOV 7UNKNOWN 6

Study Type

Interventional 7

Sponsor

Cancer Type

Breast 7

Conditions

Breast Neoplasms 3HER2 Positive Breast Cancer 2Metastatic Breast Cancer in the Brain 1HER2 Positive Metastatic Breast Cancer 1

Interventions

Cisplatin 50Capecitabine 42apatinib 34Radiotherapy 33Oxaliplatin 33Gemcitabine 33Cyclophosphamide 32Drug Therapy 31Paclitaxel 30Carboplatin 29tislelizumab 27Irinotecan 27Fluorouracil 26Docetaxel 26Bevacizumab 23Surgical Procedures, Operative 21Nivolumab 19pembrolizumab 18fludarabine 18Radiation 16Metformin 16Exercise 16camrelizumab 15S 1 (combination) 14Control Groups 14Blood Specimen Collection 14Pemetrexed 13Standard of Care 12anlotinib 11Neoadjuvant Therapy 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
OTHER_GOV × pyrotinib × Clear all
NCT05769010 2026-04-01

Study of SHR-A1811 in HER2-expression Advanced Breast Cancer With Brain Metastases

Henan Cancer Hospital

Phase 2 Recruiting
150 enrolled
Breast

Breast Neoplasms

NCT06475443 2024-06-26

Efficacy of Pyrotinib Plus Capecitabine in HER2-positive MBC With Active Brain Metastases That Have Failed ADCs

Henan Cancer Hospital

Phase 2 Not yet recruiting
32 enrolled
Breast

Metastatic Breast Cancer in the Brain

NCT03691051 2023-09-25

A Study of Pyrotinib Plus Capecitabine in Patients With Brain Metastases From HER2-positive Metastatic Breast Cancer

Henan Cancer Hospital

Phase 2 Unknown
78 enrolled
Breast

HER2 Positive Metastatic Breast Cancer

NCT05328440 2023-09-25

Treatment of Dalpiciclib Combined With Pyrotinib for Trastuzumab-sensitive HER2+ Advanced Breast Cancer(DAP-Her-02)

Henan Cancer Hospital

Phase 2 Unknown
120 enrolled
Breast

Breast Neoplasms

NCT04293276 2023-05-06

DAP-Her-01

Henan Cancer Hospital

Phase 2 Unknown
41 enrolled
Breast

Breast Neoplasms

NCT03735966 2022-12-01

Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Docetaxel and Carboplatin in HER2 Positive Breast Cancer Patients.

Henan Cancer Hospital

Phase 2 Completed
75 enrolled
Breast

HER2 Positive Breast Cancer

NCT03947242 2019-05-15

Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Vinorelbine in Trastuzumab-refractory HER2-Positive Breast Cancer.

Henan Cancer Hospital

Phase NA Unknown
48 enrolled
Breast

HER2 Positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡